Q3 2020 Iovance Biotherapeutics Inc Earnings Call

Thank you for calling the conferencing center, if you do not anticipate asking your questions via the phone you can alternatively access the call audio via the webcast link provided in a press release or on the IR website, a conference coordinator will be with you momentarily. Thank you.

[noise] [noise]. Thank.

You for your patience.

Please stay on the line for the next available operator.

[music].

H E L E y.

It is Brian Healy is that correct.

That's correct.

Thank you and that May have dispelling every company name. Please.

A I.E.R.A. J.

I don't know is that correct.

Yes, that's correct.

Thank you on hold until the conference begins have a good evening.

Thank you.

Then we have the core biopsy cohort, which is really a signal generation proof of concept.

The objective that is sized at an equal 50, and and then called floors is not defined with a with a subject size. Because these are patients who fail on either cohort one through three so that's not not really as statistically powered affair. This is basically a again signal searching.

And enrolled from patients that are coming from the studies hope that makes sense.

Yes Super helpful. Thanks for taking the question sure.

Thank you.

Our next question comes from the line of bore speaker with Cowen.

Great. Thanks for taking my questions first on the long how can you comment when we're going to be seeing your lung cancer data.

Hi, Boris Good afternoon, you have you have now committed to a specific timeline for our lung data to be released.

Is that correct answers that regardless of what the data you're going to see with your long data.

Your own long study you are going to proceed with the pivotal trial.

I don't know if that's necessarily the correct statement just the fact that we haven't released it doesn't mean, we haven't seen it. So obviously, we have enthusiasm behind indication to start the study.

Gotcha, Okay. Maybe lastly, just curious what commercial preparations rate, making from us to lose so I had a launch and maybe given learn from parties.

Any mistakes that were made there to make sure they are not made again.

Absolutely I'm going to pass the question to Jim sure our launch preparations continue.

As we have started earlier this year along three major fronts first is site preparation and onboarding.

Second is ensuring that our I O Vance carousel ordering and patient system. So.

Support system is ready for launch and then third working with payers. So on the first.

Uh-huh.

Well, hey, everyone. Thanks for taking a request so first one.

These fully on seem small cell lung cancer would it be reasonable say that say composite Mafia Peter looks at your own fruit baskets data.

The basis.

Or sorry, I mean, there's some cancer trial probably.

P D one location.

Hi, Maggie good afternoon, I'll try and answer the question. It was not very easy to hear you're getting cut off [noise].

Uhm I believe what you're wondering about is whether to connect to the experience of the data we had from mofette as well as what we may be observing internally was the basis for our selection of the patient population in L. U N. Two O two the answer to that is yes.

Okay and then.

Beyond up you'll see a response right.

Yeah, Hi, guys. Thanks for taking my questions.

Maria So it sits see you talked about the abstract having nine patients how much more data will we have next week.

I did and good afternoon I'm given.

Abstract submission deadline was moved out I'm really just a little bit of a longer follow up it will be a going to present that they see and I think abstracts are being ordered a posters are getting released on Monday, so longer follow up okay.

Adjusted Walsh on for Randy.

So I have a couple of questions. The first one is on the assay so.

So if you resolve this and we're assuming that you will resolve this for for life of loose so.

Do you expect that you could encounter similar roadblocks for later products like your genetically modified tils or or do you think that once you figure out how the FDA wants to define tails that you will be more or less in the clear for later products.

<unk> very closely with bouchey, our <unk> N O C M O provider for our manufacturing to date and there's ample capacity secured I'd lose you for us to initialize, our commercial manufacturing in the switch over to icy T. C. So we do have a number of different options do you work on all fronts to make sure that would be a complete the red.

<unk>.

Perfect. Thank you for taking the questions of course, thank you.

Your next question comes from the line of Jim Burdge enough with Wells Fargo.

[noise] can upgrade it to a nickel and forgive yourself maintenance taking of questions.

First question and you'll pay come as you know to the the type be meeting to find the juration of treatment I'm, sorry duration of follow up. So it is six months after an unconfirmed partial response and and why would it be different for cervical cancer.

<unk> a collection of tumor corporate three allows for a core biopsy, which is a much smaller amount of tumor.

Great. Thank you uhm.

And then just in terms of thinking about the new commercial.

<unk> I flew sullen melanoma uhm, how many <unk> <unk> <unk>, the surgical resection or biopsy procedure, how many's, how surgeons credential forgiving chemotherapy.

Plus multiple people it begins with let's say.

The surgical oncologists as you point out to do the tumor tissue procurement process. It involves the medical oncologist, obviously and consult with the community and in many cases and then there's that care team that surrounds. This every site is a little bit different as we're learning.

We have a follow up question from the line of Madu Kumar with Baird.

Yeah can you hear me okay.

Yes, much better thank him into <unk>, so I want to follow up on head and neck cancers. So do you have so far is largely in patients versus Q1 after chemo and as Byron mentioned, there's usually a fairly material difference in response rate between in the front line could be one population that head and neck cancer and the PD one after chemo population so.

And he was first line therapy and.

Care to sort of I suppose put some college around what thousands mean.

Yes of course.

Our CLL program had dosed, our first patient in the earlier part of the year.